electroCore

Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Apr 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-71.7%

3.8%

-71.7%

3.8%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

US$21.476.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on 01 May 25

Fair value Increased 29%

Shared on 24 Apr 25

Fair value Decreased 29%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 10%

AnalystConsensusTarget has decreased revenue growth from 32.8% to 28.0%, decreased profit margin from 29.9% to 12.9%, increased future PE multiple from 12.5x to 36.2x and decreased shares outstanding growth rate from 0.2% to 0.1%.

AnalystConsensusTarget Fair Value

US$21.4

76.9% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

25.68%

Medical Equipment revenue growth rate

7.37%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.35%

Calculation

US$17.04m

Earnings '28

18.42x

PE Ratio '28

US$313.97m

Market Cap '28

US$313.97m

Market Cap '28

11.74m

No. shares '28

US$26.73

Share Price '28

US$26.73 Share Price '28

Discounted to 2025 @ 7.70% p.a.

US$21.40

Fair Value '25